Shanghai Haohai Biological Technology Co., Ltd. (Haohai Biological) disclosed that on 21 July 2026 it repurchased 73,000 H shares on the Hong Kong Stock Exchange at prices ranging from HK$16.64 to HK$16.88 per share, incurring a total consideration of HK$1.23 million. These shares are intended for cancellation.

The latest transaction lifts the company’s aggregate buybacks under the repurchase mandate granted on 29 May 2026 to 234,000 H shares, equivalent to 0.67% of the 34.78 million H shares in issue and 0.10% of Haohai Biological’s total 224.98 million ordinary shares (comprising 190.20 million A shares and 34.78 million H shares). The board is authorised to repurchase up to 3.48 million shares; thus, 93.3% of the mandate remains.

Including the 161,000 H shares repurchased on 20 July 2026 at an average HK$16.40, a total of 234,000 shares are pending cancellation. Haohai Biological currently holds no H shares as treasury stock, while 3.85 million A shares are held in treasury.

Following the 21 July transaction, the company’s issued share capital remains unchanged at 224.98 million shares until the pending cancellations are effected. Under Hong Kong listing rules, Haohai Biological is subject to a moratorium on new share issues or treasury share sales until 20 August 2026.